Ombrabulin

DB12882InvestigationalSmall molecule

Ombrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others.

Mechanism: Pharmacologically active on Tubulin
Curator reviewed
Formula / weight: C₂₁H₂₆N₂O₆ · 402.447 g/mol (avg)
Code names: AC7700 · AVE-8062

Resolves to

Compound

UNII82JB1524Q6CAS181816-48-8ChEMBLCHEMBL572284PubChem6918405

Structure

InChIKeyIXWNTLSTOZFSCM-YVACAVLKSA-NSMILESCOC1=CC=C(\C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1NC(=O)[C@@H](N)CO

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Ombrabulin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account